RT Journal Article
SR Electronic
T1 Provisional research criteria for the behavioral variant of Alzheimer’s disease A systematic review and meta-analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.08.21263253
DO 10.1101/2021.09.08.21263253
A1 Ossenkoppele, R.
A1 Singleton, E.H.
A1 Groot, C.
A1 Dijkstra, Anke A.
A1 Eikelboom, Willem S.
A1 Seeley, William W.
A1 Miller, Bruce
A1 Laforce, R.
A1 Scheltens, P.
A1 Papma, J.M.
A1 Rabinovici, G.D.
A1 Pijnenburg, Y.A.L.
YR 2021
UL http://medrxiv.org/content/early/2021/09/13/2021.09.08.21263253.abstract
AB Importance The behavioral variant of Alzheimer’s disease (bvAD) is characterized by early and predominant behavioral deficits caused by AD pathology. This AD phenotype is insufficiently understood and lacks standardized clinical criteria, limiting reliability and reproducibility of diagnosis and scientific reporting.Objective To perform a systematic review and meta-analysis of the bvAD literature, and use the outcomes to propose provisional research criteria for this syndrome.Data sources A systematic literature search in PubMed/Medline and Web-of-Science databases (from inception through April 7th, 2021, performed in duplicate) led to the assessment of 83 studies, including 13 suitable for meta-analysis.Study selection Studies reporting on behavioral, neuropsychological or neuroimaging features in bvAD, and, when available, providing comparisons with “typical” amnestic-predominant AD (tAD) or behavorial variant frontotemporal dementia (bvFTD).Data extraction and synthesis We performed random-effects meta-analyses on group-level study results of clinical data, and systematically reviewed the neuroimaging literature.Main outcome and measures Behavioral symptoms (neuropsychiatric symptoms and bvFTD core clinical criteria), cognitive function (global cognition, episodic memory and executive functioning) and neuroimaging features (structural MRI, [18F]FDG-PET, perfusion SPECT, amyloid-PET and tau-PET).Results Data were collected for 591 patients with bvAD. There was moderate-to-substantial heterogeneity and moderate risk of bias across studies. bvAD showed more severe behavioral symptoms compared to tAD (standardized mean difference [SMD, 95% confidence interval]: 1.16[0.74–1.59], p<0.001), and a trend towards less severe behavioral symptoms compared to bvFTD (SMD:-0.22[-0.47–0.04], p=0.10). Meta-analyses of cognitive data indicated worse executive performance in bvAD versus tAD (SMD:-1.03[-1.74–-0.32], p<0.01), but not compared to bvFTD (SMD:-0.61[-1.75–0.53], p=0.29). bvAD showed a trend towards worse memory performance compared to bvFTD (SMD:-1.31[-2.75–0.14], p=0.08), but did not differ from tAD (SMD:0.43[-0.46–1.33], p=0.34). The neuroimaging literature revealed two distinct bvAD neuroimaging-phenotypes: an “AD-like” posterior-predominant pattern and a “bvFTD-like” anterior-predominant pattern, with the former being more prevalent.Conclusions and relevance Our data indicate that bvAD is clinically most similar to bvFTD, while it shares most pathophysiological features with tAD. Based on these insights, we propose provisional research criteria for bvAD aimed at improving the consistency and reliability of future research and aiding the clinical assessment of this AD phenotype.Question How does the behavioral variant of Alzheimer’s disease (bvAD) relate to typical AD (tAD) and to behavioral variant frontotemporal dementia (bvFTD) in terms of clinical presentation and neuroimaging signatures?Findings In this systematic review and meta-analysis, we found that, at time of diagnosis, bvAD showed more severe neuropsychiatric symptoms and other behavioral deficits compared to tAD. Two distinct neuroimaging phenotypes were observed across reported bvAD cases: an “AD-like” posterior-predominant pattern and a “bvFTD-like” anterior-predominant pattern, with the posterior-predominant neuroimaging phenotype being the most prevalent across reported bvAD cases.Meaning bvAD is clinically most reminiscent of bvFTD, while it shares most pathophysiological features with tAD. The provisional research criteria are aimed at improving the consistency and reliability of future research, and potentially aid in the clinical assessment of bvAD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project has received funding from the Netherlands Organization for Health Research and Development, ZonMw (70-73305-98-1214 to Rik Ossenkoppele [PI] and Janne Papma [PI]). Research of the Alzheimer Center Amsterdam is part of the neurodegeneration research programme of Amsterdam Neuroscience. The Alzheimer Center Amsterdam is supported by Stichting Alzheimer Nederland and Stichting VUmc fonds. Research at UCSF is supported by the following grants: P30-AG062422 (BLM, GDR), P01-AG019724 (BLM, GDR), R35 AG072362 (GDR), R01-AG038791 (GDR), R01-NS050915 (MLGT), R01 AG045611 (GDR), Rainwater Charitable Foundation (GDR). Research at CHU de Quebec is supported by the Chaire de recherche sur les aphasies primaires progressives - Fondation de la famille Lemaire (RJL).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All work presented has been approved by local IRB and/or medical ethics review boards.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon reasonable request.